TLR7/8 agonist 1 is an agonist of TLR7/8 that can be used as an adjuvant for skin treatment of virus-associated warts and basal cell carcinoma.

1V209 is a novel and potent Toll-like receptor 7 (TLR7) agonistwith anti-tumor activity.

E6446 is a synthetic antagonist of nucleic acid-sensing TLRs.

TLR7/8 agonist-5d is a novel and potent TLR7/8 agonist.

MD2-IN-1, a chalcone derivative, is a novel potent and specific inhibitor of Myeloid differentiation protein 2 (MD2) with potential anti-inflammatory activity.

CU-CPT-9a, an analog of CU-CPT-8m, is a potent and specific antagonist/inhibitor of TLR8 (Toll-like receptor 8) (IC50 = 0.5 nM) with the potential to be used for treating autoimmune diseases.

TLR7 agonist 2 is a novel, oral, potent and selective agonist of Toll-like Receptor 7 (TLR7) with antiviral activity.

Imiquimod (S-26308; R-837; TMX-101; Aldara; Zyclara) is an immune response modifier that acts as an agonist of the TLR7 (toll-like receptor 7).

Schaftoside is a novel and potent flavonoid compound.

CU-CPT-9b, an analog of CU-CPT-8m and CU-CPT-9a, is a specific antagonist of TLR8 (Toll-like receptor 8) with IC50 of 0.7 nM.